Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still in develop for the convenience of multiple myeloma (MM) patients.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read